Kayne Anderson Rudnick Investment Management
PRAX icon

Kayne Anderson Rudnick Investment Management’s Praxis Precision Medicines PRAX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed -$1K – 662
2022
Q1 		$1K Buy
+5
New +$1.03K ﹤0.01% 641

Other funds holding PRAX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's PRAX Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Praxis Precision Medicines (PRAX) in Q2 2022, closing a stake of 5 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in PRAX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 95 funds tracked by Wall St. Rank hold PRAX as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Praxis Precision Medicines position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 5 Praxis Precision Medicines shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Praxis Precision Medicines in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Praxis Precision Medicines position peaked at $1K in Q1 2022.
  • 95 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.